Adult patients under 65 were less likely to delay treatment and had less trouble paying for medications or dental care after key features of the landmark health care law were implemented.

A new blood test could give doctors more time to try alternative treatments for HPV-positive throat cancer by signaling whether initial treatment is effective much earlier than current diagnostic tests.

Activity of the polycomb repressive complex 1 is essential for the development and maintenance of leukemic cells; disrupting it presents a new potential therapeutic approach.

Some prostate tumors transition from being glandular to more nerve-like in response to drugs that block the androgen receptor; a new preclinical study examines the underlying mechanisms and uncovers a promising countermeasure.

In 25 years, Chris Cauley had never taken two weeks off of work. As health services were shutting down because of COVID-19, he had to learn how to be a patient.

Findings offer clues to why some types of renal cell carcinoma respond to immunotherapy while others do not.

ApoE has known roles in cardiovascular disease and Alzheimer’s, but was not previously implicated in pancreatic cancer.

The U.S. Preventive Services Task Force has lowered the recommended age of colorectal cancer screenings to 45 due to a rise in colorectal cancer cases among the younger population.

Approach opens a new avenue to study the biology of acute leukemia and for the development new drugs.

Stopping the interaction between KRAS and the protein AGO2 slowed tumor growth in mouse models.

Vaccines and other policies could help keep in check a disease that’s becoming increasingly common worldwide.

Using next-generation sequencing, the UPSeq test assesses 15 biomarkers to find aggressive prostate cancer that can be missed by biopsies or imaging tests.

MiTF renal cell carcinoma can masquerade as other subtypes and may not respond as well to front-line therapies.

Study findings support the recent FDA approval of the immunotherapy agent for patients whose cancers have high number of mutations.

Clinical guidelines have encouraged the integration of palliative care, yet medicine lags far behind its goals for ovarian cancer, especially for people of color